# Neurosterix

> Clinical-stage neuropsychiatry developer designing selective brain-receptor modulators, led by investigational oral M4 programme NTX-253 for schizophrenia.

## Why it is interesting

Announced a $105M RTW-led Series B on November 12, 2026 after a $63M April 2024 Series A. Its Phase 1 NTX-253 study has completed and Phase 2 remains planned. The muscarinic mechanism has clinical precedent, but Neurosterix's candidate has not demonstrated Phase 2 efficacy or gained approval.

## Profile

- **Latest funding:** Series B — $105M (November 12, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $168M
- **Stage:** series-b
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-13
- **Latest funding investors:** RTW Investments, Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors, Dellora Investments, Perceptive Advisors, Acorn Bioventures

## Key facts

- $105M Series B led by RTW Investments, announced Nov 12, 2026; $63M Series A in April 2024 led by Perceptive Xontogeny Venture Fund II.
- The company describes total financing as approximately $170M, while $63M + $105M = $168M across the two separately announced rounds.
- Completed Phase 1 trials are not proof of efficacy in people with schizophrenia; Phase 2 is planned, not completed.
- NTX-253 is a selective muscarinic M4 positive allosteric modulator; NTX-819 and NTX-529 are separate development programmes.
- Addex contributed the originating small-molecule discovery platform and other assets in 2024; no 2026 IPO or acquisition has been announced.

## Funding history

- Series B · $105M · November 12, 2026
  Source: https://www.businesswire.com/news/home/20261112398888/en/
- Series A · $63M · April 3, 2024
  Source: https://www.businesswire.com/news/home/20240402425104/en/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/neurosterix